Growth Metrics

Adaptive Biotechnologies (ADPT) Gains from Investment Securities (2018 - 2025)

Historic Gains from Investment Securities for Adaptive Biotechnologies (ADPT) over the last 8 years, with Q3 2025 value amounting to $11.1 million.

  • Adaptive Biotechnologies' Gains from Investment Securities fell 1087.91% to $11.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.1 million, marking a year-over-year decrease of 1087.91%. This contributed to the annual value of $12.3 million for FY2024, which is 450.29% down from last year.
  • Per Adaptive Biotechnologies' latest filing, its Gains from Investment Securities stood at $11.1 million for Q3 2025, which was down 1087.91% from $11.4 million recorded in Q2 2025.
  • Adaptive Biotechnologies' 5-year Gains from Investment Securities high stood at $156.5 million for Q4 2021, and its period low was -$76000.0 during Q1 2025.
  • In the last 5 years, Adaptive Biotechnologies' Gains from Investment Securities had a median value of $12.8 million in 2021 and averaged $17.0 million.
  • As far as peak fluctuations go, Adaptive Biotechnologies' Gains from Investment Securities plummeted by 12500.0% in 2023, and later surged by 27187624.0% in 2024.
  • Over the past 5 years, Adaptive Biotechnologies' Gains from Investment Securities (Quarter) stood at $156.5 million in 2021, then crashed by 95.16% to $7.6 million in 2022, then tumbled by 79.35% to $1.6 million in 2023, then crashed by 77.44% to $353000.0 in 2024, then soared by 3033.38% to $11.1 million in 2025.
  • Its Gains from Investment Securities was $11.1 million in Q3 2025, compared to $11.4 million in Q2 2025 and -$76000.0 in Q1 2025.